Results - Announcements
Corona Remedies Ltd share price declined by 3.12% to Rs 2146.05. The Company's net profit inched up 0.33% to Rs 60.31 crore, while revenue from operations improved marginally 4.44% to Rs 441.17 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.58 lakh crore, easing 4.48%. It has marginally improved by 6.57% over last one week and crept higher by 1.39% in last one month while the market capitalization of Corona Remedies Ltd has improved by 4.45% and 2.31% in the same period respectively.
Profit before tax (PBT) of Corona Remedies Ltd stood at Rs 80.75 crore in Q3 FY26, rallying 15.72% year-on-year, and gaining 0.49% quarter-on-quarter. EBITDA came in at Rs 93 crore, expanding by 22.66% YoY and rising 3.88% sequentially.
Total expenses posted a minor rise of 5.18% to Rs 360.28 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 35.01 crore, growing marginally by 7.23% YoY, while employee benefits expense was at Rs 124.24 crore, ticking higher by 1.76% YoY.
For the TTM ended FY26, revenue from operations improved 17.28% to Rs 1403.18 crore, while net profit soared by 23.88% to Rs 185.12 crore, compared to previous TTM. EBITDA surged by 23376% to Rs 282.79 crore, and PBT surged 21.10% to Rs 240.42 crore compared to previous TTM.
The company's consolidated net cash flow from operating activities stood at Rs 229.48 crore in FY26, as against Rs 190.5 crore in FY25.
Corona Remedies Ltd jumped 49.32% in last one year, significantly outperforming the benchmark BSE Sensex which has declined by 11.78% during the same period.